More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO

PharmaTher Holdings Ltd. PHRRF continues on its path to becoming the leader in specialty ketamine products. A new product, developed in collaboration with the leader in design and manufacturing of wearable pen and auto injectors, CC Biotechnology Corporation, will combine PharmaTher’s ketamine formulation with CCBIO’s Felice Dose wearable delivery device. Clinical trials are expected to take place in the first months of 2023.

What The Innovation Implies For Ketamine Treatments

Ketamine, applied intravenously (IV) and intramuscularly (IM) for analgesia, sedation and anesthetic induction, is also emerging as a plausible option for treating various mental health, neurological and pain disorders, most notably Parkinson’s disease

As such, moving from IV and IM to wearable injection systems and microneedle patches could facilitate compliance and dose flexibility for both caregivers and patients. The new subcutaneous format might also improve safety and efficacy, reduce side effects, enhance patient comfort and adherence and reduce the time burden of treatment on patients and healthcare providers whether in hospital, clinic or at home.

“In addition, the current, evolving, and future therapeutic use of ketamine is dependent on the control of ketamine dosing to deliver pharmacokinetic profiles specific to each indication." said PharmaTher CEO Fabio Chianelli. "Therefore, our goal is to become a leader in specialty ketamine solutions, which include injectable, intravenous, microneedle patch and now a ketamine wearable device that each serve a unique solution to enable tailored pharmacokinetic profiles for various mental health, neurological, and pain disorders.”

How It Would Work

CCBio’s Felice Dose is a delivery motor system based on a body subcutaneous injector device that works for various drug volumes, concentrations and viscosities over variable and long-duration injections. It can deliver a stable dose of drug per unit time under discontinuous pressure, reducing the skin-swelling during injection and thus decreasing patient pain.

In addition, the system can adapt to the primary drug container, providing a very stable displacement unit for the drug, and the duration for filling and delivery can be programmed to suit the drug formulation.

In the present collaboration, CCBIO will be responsible for the development and clinical manufacturing activities and support PharmaTher’s regulatory submissions towards the production and commercialization of the new wearable ketamine delivery device.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechCannabisNewsPenny StocksPsychedelicsMarketsGeneralCCBIOPharmaTher Holdings Ltd.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!